ContributorsPublishersAdvertisers

Lenvatinib May Provide Survival Benefit With Manageable Toxicities in Recurrent HCC After Liver Transplantation

onclive.com
 2022-01-21

Lenvatinib was effective in treating patients with recurrent hepatocellular carcinoma after liver transplantation and demonstrated manageable toxicities. Lenvatinib (Lenvima) was effective in treating patients with recurrent hepatocellular carcinoma (HCC) after liver transplantation and demonstrated manageable toxicities, according to a recent retrospective study. Outcomes from the single-center study, which was...

www.onclive.com

Comments / 0

Comments / 0